Amer Zeidan, Yuexi Wang, Rebekah Yu, Aliza Matusevich, Ruizhi Zhao. "Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)." Blood, 2025. doi:10.1182/blood-2025-8176